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Morusin, the important active component of a traditional Chinese medicine, Morus alba L., has been shown to exhibit many
vital pharmacological activities. In this study, six recombinant CYP450 supersomes and liver microsomes were used to perform
metabolic studies. Chemical inhibition studies and screening assays with recombinant human cytochrome P450s were also used
to characterize the CYP450 isoforms involved in morusin metabolism. The morusin metabolites identified varied greatly among
different species. Eight metabolites of morusin were detected in the liver microsomes from pigs (PLMs), rats (RLMs), andmonkeys
(MLMs) by LC-MS/MS and six metabolites were detected in the liver microsomes from humans (HLMs), rabbits (RAMs), and
dogs (DLMs). Four metabolites (M
1
, M
2
, M
5
, and M
7
) were found in all species and hydroxylation was the major metabolic
transformation. CYP1A2, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP2C19 contributed differently to the metabolism of
morusin. Compared to other CYP450 isoforms, CYP3A4 played the most significant role in the metabolism of morusin in human
liver microsomes. These results are significant to better understand the metabolic behaviors of morusin among various species.
1. Introduction
Flavonoids and their derivatives are important components
of the human diet and exhibit many diverse pharmacological
effects [1, 2]. Morusin (Figure 1) is a prenylated flavonoid
that was first isolated from the root bark of Morus alba L. in
1978 and then later characterized in 2001 [3, 4]. In previous
studies, we discovered thatmorusin exhibits strong inhibitory
activity against primary UGTs and CYP450s. Additionally,
our findings revealed significant differences in itsmetabolism
between species and found that dog models are the optimum
model to study morusin metabolism [5].
Like most flavonoids, morusin has antitumor [6, 7], anti-
inflammatory [8], and antibacterial [9] activity. However, it is
unclear if morusin or its metabolites produce these biological
activities. Additionally, the side effects and toxic reactions
of morusin may also be related to its metabolites. Therefore,
determination of only the parent drug may not fully reflect
its true pharmacologic and toxic nature. Identification of
metabolites of a potential drug candidate plays an important
role in drug development and can provide essential informa-
tion on drug efficacy and its toxicological profile. Recently,
metabolic studies have been performed in the early stages
of drug discovery to determine whether the potential drug
candidate is worth further development [10].
A simple and effective analytical method to reveal the
structures of possible active constituents is a significant and
valuable tool. Mass spectrometry coupled to liquid chroma-
tography (LC-MS) [11, 12], mass spectrometry coupled to
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Figure 1: The structure of morusin.
gas chromatography (GC-MS) [13, 14], and nuclear magnetic
resonance (NMR) [15, 16] aremost frequently used to identify
the structures of drugs. Compared to GC-MS or NMR, LC-
MS based techniques are often used for metabolite identifi-
cation due to their superior selectivity, sensitivity, and rapid
rate of analysis [12].
In this study, the morusin metabolite profiling was per-
formed through ultraperformance liquid chromatography/
electrospray ionization quadruple time-of-flight/high-def-
initionmass spectrometry (UPLC/ESI-Q-TOF/HDMS) com-
binedwith pattern recognition approaches and pathway anal-
ysis.The system has proven to have higher sensitivity than the
traditional high-resolution MS system and has been used to
identify many drug structures [17, 18]. In addition, CYP450
isozymes involved in the metabolism of morusin were also
confirmed by assays with recombinant CYP450 isoforms and
chemical inhibition experiments. Finally, molecular docking
was employed to further understand the interactions between
morusin and CYP450s.
2. Materials and Methods
2.1. Materials. Morusin was purchased from Shifeng Corp in
Shanghai, China, and its purity was above 98%. Furafylline,
xanthotoxin, quercetin, sulfaphenazole, omeprazole, quini-
dine, clomethiazole, ketoconazole, glucose-6-phosphate de-
hydrogenase, NADP+, D-glucose-6-phosphate, 4-methy-
lumbelliferone (4-MU), 4-methylumbelliferone-𝛽-D-glucu-
ronide (4-MUG), Tris-HCl, 7-hydroxycoumarin, and uridine
5󸀠-diphosphoglucuronic acid (UDPGA) (trisodium salt)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Recombinant human supersomes (CYP1A2, CYP2C9,
CYP2D6, CYP2E1, CYP3A4, and CYP2C19) were obtained
from BD Gentest Corp. (Woburn, MA, USA). All other
reagents were of HPLC grade or of the highest grade com-
mercially available.
2.2. Preparation and Characterization of Liver Microsomes.
Liver microsomes from humans (HLMs), monkeys (MLMs),
rabbits (RAMs), rats (RLMs), dogs (DLMs), and minipigs
(PLMs)were provided by the Research Institute for LiverDis-
ease Co. (Shanghai, China). The HLMs were prepared from
eleven individual human donor livers. MLMs, RAMs, RLMs,
DLMs, and PLMs were prepared from ten individual animal
livers. Protein concentration and microsome activities of
CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6,
CYP2E1, and CYP3A4 had been previously characterized by
the Research Institute for Liver Disease Co.
2.3. Analytical Instruments and Conditions. The HPLC con-
ditions have been elaborated by us previously [5]. Briefly,
HPLC system (Shimadzu, Kyoto, Japan) consisted of a CBM-
20Alite system controller, two LC-20AB pumps, and an SPD-
20A ultraviolet light (UV) detector. The chromatographic
separationwas performedon aC18 column (4.6mm: 150mm,
5mmKromasil). The mobile phases A and B comprised 0.1%
formic acid in water and acetonitrile, respectively. The gradi-
ent profiles were as follows: 0–12min, 55%B; 12-13min, 55–
90%B; 13–19min, 90%B; 19-20min, 90–55%B; 20–25min,
55%B. The flow rate, column temperature, and wavelength
were set as 1mL/min, 40∘C, and 270 nm, respectively.
LC-MS/MS analysis was performed on Ultra-Perform-
ance LiquidChromatograph (UPLC) equippedwith aQ-TOF
SYNAPT G2-Si High Definition Mass Spectrometry (Waters
Corporation, Milford, MA). Each sample (2 𝜇L) was injected
into aWelch C18 column (1.7mm × 100mm, 1.7 𝜇m,Milford,
USA) using anAcquityH-classUPLC system (Waters Corpo-
ration, USA). The column oven was maintained at 40∘C.The
mobile phase consisted of LC grade water with 0.1% formic
acid (A) and LC grade acetonitrile (B) with the following
gradient profile: 0–12min, 55%B; 12-13min, 55–90%B; 13–
19min, 90%B; 19-20min, 90–55%B; 20–25min, 55%B. The
mass spectrometer was operated in negative mode and the
mass range was set from 100𝑚/𝑧 to 500𝑚/𝑧. Optimum
parameters were as follows: ESI collision gas was Argon, trap
collision energies were 6V (low energy) and 20–50V (high
energy), the capillary and cone voltages were 2KV and 40V,
the source and desolvation temperatures were 120 and 600∘C,
and the cone and desolvation gas flowswere 50 and 800 L⋅h−1.
2.4. Incubation Systemswith LiverMicrosomes or Recombinant
CYP450 Supersomes. The optimum incubation conditions
of microsomes have been reported [5]. In brief, the typ-
ical incubation system contains 100mM potassium phos-
phate buffer (pH 7.4), a NADPH-generating system (1mM
NADP+, 10mM glucose-6-phosphate, 1 unit/mL of glucose-
6-phosphate dehydrogenase, and 4mM MgCl
2
), the appro-
priate concentration of liver microsomes or recombinant
CYP450s supersomes, the corresponding probe substrate,
and morusin (or positive inhibitor for different probe reac-
tions) in a final volume of 200𝜇L. According to preliminary
experiments (data not shown), the final protein concentra-
tion of 0.3mg/mL in liver microsomes or 15 nM in recom-
binant human supersomes and a 30min reaction time were
selected to ensure linear formation of metabolites during the
incubations. There was a 3min preincubation at 37∘C before
the reaction was initiated by adding the NADPH-generating
system. The reaction was placed on ice and terminated by
adding 200𝜇L acetonitrile and an internal standard. The
mixture was centrifuged at 20,000×g for 20min and an
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aliquot (10 𝜇L) of supernatant was transferred for HPLC or
LC-MS/MS analysis.
2.5. Assay with Recombinant P450s. Six cDNA-expressed
human CYP isoforms (CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP2E1, and CYP3A4) were used to screen the
involved isoform(s) formorusinmetabolites.The incubations
were carried out with each of the CYP450 isoforms using the
protocol described above. Morusin (10 𝜇M) was incubated
with each of the recombinant CYP450s (15 nM) at 37∘C for
60min and potential metabolites were monitored by HPLC.
2.6. Chemical Inhibition Assays. In this study, morusin
metabolism in HLMs was measured in the absence or pres-
ence of selective inhibitors for CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP2E1, and CYP3A4 to explore the enzyme(s)
involved in the biotransformation of morusin. The positive
control inhibitors of individual CYP450 isoforms were as fol-
lows: furafylline (10𝜇M) for CYP1A2, xanthotoxin (2.5 𝜇M)
for CYP2A6, quercetin (2𝜇M) for CYP2C8, sulfaphenazole
(10 𝜇M) for CYP2C9, omeprazole (20𝜇M) for CYP2C19,
quinidine (10 𝜇M) for CYP2D6, clomethiazole (50 𝜇M) for
CYP2E1, and ketoconazole (1 𝜇M) for CYP3A4.
2.7. Docking Studies of Morusin into the Reported Structures
of CYP3A4. In order to further assess morusin metabolism
by CYP3A4, molecular docking analysis with Gold v5.2
was implemented. This docking method has been reported
previously [19]. The crystal structures of human CYP3A4
(pdb: 4K9W) were obtained from RCSB Protein Databank
(http://rcsb.org/). SYBYL X2.1 was used for protein and
ligand preparation, and energy minimization was completed
through the external Tripos force field. The protonation state
and energy minimization of the protein and the ligands were
calculated using the default settings in SYBYL X2.1. The
docked poses were scored usingCHEMPLP scoring function.
The highest scored docked pose of the ligand was visualized
using Pymol Molecular Graphics System v1.3.
3. Results
3.1. Identifying CYP450s Involved in the Metabolism of Mor-
usin. cDNA-expressed human P450 isoforms were used to
investigate the enzymes involved in the formation of M
1
.
Quantification of M
1
in HLMs was normalized to 100%
and other enzymes including CYP3A4, CYP2C19, CYP2D6,
CYP2E1, CYP2C9, and CYP1A2 were compared with its
counterpart from HLM incubation. As shown in Figure 2,
the amount ofM
1
generated byCYP3A4, CYP2C19, CYP2D6,
CYP2E1, CYP2C9, and CYP1A2 was 22.6%, 6.4%, 0.6%,
1.7%, 5.9%, and 2.1% of the amount incubated in HLMs,
respectively. In addition, we also used chemical inhibition
assays to confirm the key role of CYP450s in metabolizing
morusin. The formation of M
1
could be potently inhibited
by ketoconazole (a potent inhibitor of CYP3A4) to less than
20% activity, while the selective inhibitors of other CYP450
isoforms hadminor effects on the formation ofM
1
(Figure 3).
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Figure 2: Representative HPLC profiles of morusin and its metabo-
lites in cDNA-expressed human P450 isoforms and liver human
microsomes.
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Figure 3: Inhibition assays of morusin metabolism by selective
CYP450 inhibitors in HLM. Results were mean ± SEM of at least
3 separate assays.
3.2. Structure Characterization of Metabolites by LC-MS/MS.
In this study, the biotransformation of morusin was investi-
gated by incubatingmorusin with different liver microsomes.
Eight metabolites (M
1
–M
8
) were identified from MS and
MS/MS data. All of the morusin metabolites were detected
in PLMs, RLMs, and MLMs. Six metabolites were detected
in HLMs (M
1
–M
3
, M
5
–M
7
), RAMs (M
1
–M
3
, M
5
, M
7
, and
M
8
), and DLM (M
1
, M
2
, and M
4
–M
7
). Morusin metabolite
data is listed in Table 1, and the structural skeleton ofmorusin
and its potential metabolic pathways are shown in Figure 4.
The parent compound, morusin, had a retention time of
9.17min and was easily elucidated from the standard by
comparison of retention time and MS data. Morusin (𝑚/𝑧
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Table 1: 𝑚/𝑧 of [M-H]− measurements for the protonated molecules of metabolites in rat, monkey, pig, rabbit, human, and dog liver
microsomes.
Number 𝑡
𝑅
Formula Mass Fragment Error(ppm) Metabolic reaction
Species
Rats Monkey Pigs Rabbits Human Dog
M
0
9.17 C
25
H
24
O
6
419.1545
350, 349, 335,
321, 309, 297,
217, 201, 191,
147, 121
+1.1 Parent D D D D D D
M
1
8.66 C
25
H
24
O
7
435.1392 377, 325, 313,217, 191, 121 +0.2 Hydroxylation D D D D D D
M
2
7.15 C
25
H
24
O
7
435.1451
417, 393, 377,
375, 351, 313,
217, 191
−0.2 Hydroxylation D D D D D D
M
3
7.50 C
25
H
22
O
7
433.1195 401, 379, 361,346, 291 −0.1
Hydroxylation +
dehydrogenation D D D D D ND
M
4
7.09 C
25
H
22
O
7
433.1285 401, 361 +2.2 Hydroxylation +dehydrogenation D D D ND ND D
M
5
8.82 C
25
H
26
O
8
453.1515
435, 350, 332,
325, 313, 309,
285, 235, 217,
191, 121
+0.6 2 × hydroxylation+ reduction D D D D D D
M
6
8.10 C
25
H
26
O
8
453.1528
421, 393, 381,
350, 325, 313,
285, 235, 217,
191, 121
−2.6 2 × hydroxylation+ reduction D D D ND D D
M
7
8.34 C
25
H
26
O
7
437.1389
419, 365, 339,
315, 297, 257,
219, 217, 191,
121
+1.9 Hydration D D D D D D
M
8
8.77 C
25
H
24
O
8
451.1393 433, 419, 381,375, 360, 333 +0.2 2 × hydroxylation D D D D ND ND
D, detected; ND, not detected.
419.1545) exhibited eleven characteristic fragment ions at𝑚/𝑧
values of 350, 349, 335, 321, 309, 297, 217, 201, 191, 147, and
121 (Figure 5(a)). Fragment ions at𝑚/𝑧 217.0561 and 201.0641
were produced by retro-Diels-Alder (RDA) cleavage and
further fragmented to produce 𝑚/𝑧 191.0776 and 147.0441.
The fragment ion at𝑚/𝑧 191.0776 was produced from parent
ion at 𝑚/𝑧 217.0561 through losing a CO and adding two
hydrogens at C-10. The fragment ion at 𝑚/𝑧 335.0574 was a
daughter ion of parent ion at 349.0852 by losing -CH
2
.
M
1
and M
2
were isomers with the same molecular
formula (C
25
H
24
O
7
) but differentMS/MS and retention times
(7.15 and 8.66min). They showed a 𝑚/𝑧 of 16Da more than
morusin indicating that the two metabolites were hydroxy-
lated morusin occurring at C-5󸀠 and C-14, respectively. The
cleaved pathways and fragment ions of M
1
and M
2
are shown
in Figures 5(b) and 5(c). The product ion at 𝑚/𝑧 351.0890
could be generated from a neutral loss (-C
5
H
8
OH) at C-3.
The fragment ion at 𝑚/𝑧 377 was a cyclization product from
M
1
or M
2
occurring at C-14 and C-2󸀠-OH.
M
3
andM
4
had the samemolecular formula of C
25
H
22
O
7
and showed a 𝑚/𝑧 of 2Da less than M
1
or M
2
. According to
the cleaved pathways and fragment ions of M
3
andM
4
shown
in Figures 5(d) and 5(e), theywere identified as the cyclization
and dehydrogenation products of M
1
and M
2
, respectively.
The cyclized sites ofM
3
orM
4
occurred at C-11 and C-2󸀠-OH.
M
3
underwent dehydration reaction and further produced
the fragment ions at 𝑚/𝑧 291, 361, and 401. Thus, M
3
was
inferred to have a hydroxyl at C-5󸀠. BecauseM
3
was produced
fromM
1
, we inferred M
1
also had a hydroxyl at C-5󸀠.
M
5
and M
6
were also isomers with the same molecular
formula of C
25
H
26
O
8
(𝑚/𝑧 453.1515) but different retention
times. The ionized form of M
5
and M
6
was 34Da more than
the parent compound. According to the MS/MS spectra and
information shown in Figures 5(f) and 5(g), M
5
andM
6
were
identified as the reduction and dihydroxylation products of
morusin. Exact mass determination and the corresponding
chemical composition verify that M
5
was produced through
the addition of two hydroxyl groups to the parent molecule
at C-12 and C-5󸀠. M
6
also has twomore hydroxyl groups than
morusin: one hydroxyl group was added in phenyl and the
other hydroxyl group was added at C-12.
The molecular formula of M
7
was determined to be
C
25
H
26
O
7
(𝑚/𝑧 437.1389) based on MS data and its ionized
form was 18Da more than the parent morusin. According to
its molecular formula and MS/MS spectra, M
7
was identified
as the hydration product of morusin where the hydroxyl
group was bonded to C-12. Structural formula and fragmen-
tation pathway of M
7
are shown in Figure 5(h).
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The ionized form of M
8
appeared at 𝑚/𝑧 451.1393 and
was 32Da more than morusin. Additionally, corresponding
main fragment ions were found at 𝑚/𝑧 433.1366, 419.1509,
381.0969, and 375.0877. Therefore, M
8
was identified as
a dihydroxylation product of morusin. According to the
structures of fragment ions, the two new hydroxyl groups are
potential bonded to C-14 and C-5󸀠 (Figure 5(i)).
3.3. Analysis of Docking Results. CYP3A4 is the major en-
zyme involved in the metabolism of morusin. Therefore, we
used molecular docking to study the molecular mechanism
of interactions between morusin and CYP3A4. As shown
in Figure 6, morusin binds to the active cavity of CYP3A4
through hydrogen bonding and 𝜋-𝜋 stacking interactions.
The hydrogen bonds occur with Arg106, MET371, Arg372,
andGlu374, and𝜋-𝜋 stacking interactions occur with Phe108.
4. Discussion
Morusin has many significant properties including antitu-
mor, antibacterial, and anti-inflammatory properties and
its pharmacological effects have been studied thoroughly.
However, the metabolic pathway and behavior of morusin in
human and experimental animals vary greatly and have not
been examined. In this study, a comparison of metabolic pro-
files, enzymes involved, and catalytic efficiency of morusin
metabolism in liver microsomes from different species was
performed.
It is necessary during a toxicity assessment to identify the
enzyme(s) involved in morusin biotransformation in order
to predict potential metabolite-drug interactions [20]. We
identified CYP450 isoforms involved inmorusinmetabolism
through screening assays with commercially available cDNA-
expressed CYP450 isoforms including CYP1A2, CYP3A4,
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Figure 5: Continued.
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Figure 6: Binding mode of morusin with CYP3A4. Morusin is
shown in cyan, hydrogen bonds are displayed in purple dotted lines,
and 𝜋-𝜋 stacking is displayed in a yellow dotted line.
CYP2E1, CYP2C9, CYP2D6, and CYP2C19. Of the six CYP
isoforms, CYP3A4was identified as the enzymemost respon-
sible for M
1
formation. Nevertheless, each of the six isoforms
that catalyze the metabolism of morusin was weaker than
when incubated in HLMs. This may be the reason that
morusin displayed strong inhibition to CYP450s [5]. In addi-
tion, chemical inhibition studies were performed to confirm
the CYP450 isoform that catalyzes morusin metabolism and
the results indicated that theCYP3A4-specific inhibitor, keto-
conazole, potently inhibited the formation of M
1
. Therefore,
these results verified that morusin is primarily catalyzed by
CYP3A4 in comparison to other CYP450 isoforms. Molec-
ular docking studies also confirmed that morusin binds in
the active cavity of CYP3A4 and interacts through hydrogen
bonds and 𝜋-𝜋 stacking. CYP3A4 has been identified as
the important isozyme involved in the metabolism of many
flavonoids such as nobiletin [21] and ipriflavone [22].
This study presents the fragmentation pathways of mor-
usin through implementation of LC-MS/MS in negative ion
mode and investigates its metabolites and metabolic path-
ways in six species.The results indicate that eight metabolites
of morusin are primarily biotransformed through hydroxyla-
tion, reduction, cyclization, dehydrogenation, and dehydra-
tion reactions. Flavonoids with remarkable regioselectivity
at the benzoannelated pyran ring are often formed through
Retro Diels-Alder (RDA) reactions [23]. M
0
, M
1
, M
2
, M
5
,
M
6
, andM
7
were identified as themetabolites that underwent
the RDA process. Under the effect of LC-MS/MS, M
3
, M
5
, or
M
8
occurred dehydration reaction in phenyl and produced
the corresponding fragment ions. Thus, we inferred that M
3
,
M
5
, or M
8
had a hydroxyl at C-5󸀠. Because M
3
was the
dehydrogenation product of M
1
, M
1
maybe has a hydroxyl at
C-5󸀠. All morusin metabolites were detected in PLMs, RLMs,
and MLMs, which was consistent with previous publications
which stated that pigs, rats, and monkeys have a greater
capacity to metabolize morusin [5]. M
1
, M
2
, M
5
, andM
7
were
found in all species, which indicated that hydroxylation
was the major metabolic transformation of morusin. This
novel in vitro morusin metabolism information provided in
our investigation is vital to develop a new drug and better
understand the safety and efficacy of the drug.
In conclusion, eight metabolites from morusin were
observed in the liver microsome incubation system and
hydroxylation was the major metabolic transformation.
CYP3A4 was the major isozyme involved in morusin metab-
olism, and molecular docking studies signified that morusin
binds to CYP3A4 through hydrogen bonds and 𝜋-𝜋 inter-
actions. Identification of the metabolites and metabolic
enzymes for morusin is an important contribution to fully
understand the pharmacological and toxicological profile of
morusin its pharmacological and toxicological study.
Competing Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contributions
Xianbao Shi and Brianna Mackie contributed equally to this
work.
Acknowledgments
The authors acknowledge the financial support from the
Natural Science Foundation of LiaoningProvince (Project no.
2014022005).
References
[1] A. Wojakowska, A. Piasecka, P. M. Garc´ıa-Lo´pez et al., “Struc-
tural analysis and profiling of phenolic secondarymetabolites of
Mexican lupine species using LC-MS techniques,” Phytochem-
istry, vol. 92, pp. 71–86, 2013.
[2] C. Li, A. Schmidt, E. Pichersky, F. Shi, and A. D. Jones, “Identifi-
cation of methylated flavonoid regioisomeric metabolites using
enzymatic semisynthesis and liquid chromatography-tandem
mass spectrometry,” Metabolomics, vol. 9, no. 1, pp. S92–S101,
2013.
[3] T. Nomura, T. Fukai, and M. Katayanagi, “Kuwanon A, B, C
and oxydihydromorusin, four new flavones from the root bark
of the cultivated mulberry tree (Morus alba L.),” Chemical and
Pharmaceutical Bulletin, vol. 25, no. 3, pp. 529–532, 1977.
[4] Y.-S. Chi, H.-G. Jong, K.-H. Son, H.-W. Chang, S.-S. Kang, and
H. P. Kim, “Effects of naturally occurring prenylated flavonoids
on enzymes metabolizing arachidonic acid: cyclooxygenases
and lipoxygenases,” Biochemical Pharmacology, vol. 62, no. 9,
pp. 1185–1191, 2001.
[5] X.-B. Shi, S.-M. Yang, G. Zhang et al., “The differentmetabolism
of morusin in various species and its potent inhibition against
UDP-glucuronosyltransferase (UGT) and cytochrome p450
(CYP450) enzymes,” Xenobiotica, vol. 46, no. 5, pp. 467–476,
2016.
[6] C. Kim, J. H. Kim, E. Y. Oh et al., “Blockage of STAT3 signaling
pathway by morusin induces apoptosis and inhibits invasion in
human pancreatic tumor cells,” Pancreas, vol. 45, no. 3, pp. 409–
419, 2016.
10 Evidence-Based Complementary and Alternative Medicine
[7] B. Ding, Y. Lv, and Y.-Q. Zhang, “Anti-tumor effect of morusin
from the branch bark of cultivated mulberry in Bel-7402 cells
via theMAPK pathway,”RSCAdvances, vol. 6, no. 21, pp. 17396–
17404, 2016.
[8] H. J. Lee, J. Ryu, S. H. Park et al., “Effects ofMorus alba L. and
natural products including morusin on In vivo secretion and
In vitro production of airway MUC5ACmucin,” Tuberculosis &
Respiratory Diseases, vol. 77, no. 2, pp. 65–72, 2014.
[9] H.-Y. Sohn, K. H. Son, C.-S. Kwon, G.-S. Kwon, and S. S. Kang,
“Antimicrobial and cytotoxic activity of 18 prenylated flavonoids
isolated frommedicinal plants:Morus alba L.,Morus mongolica
Schneider, Broussnetia papyrifera (L.) Vent, Sophora flavescens
Ait and Echinosophora koreensis Nakai,” Phytomedicine, vol. 11,
no. 7-8, pp. 666–672, 2004.
[10] H. Ouyang, M.-F. Zhou, Y.-C. Guo et al., “Metabolites profiling
of Pulsatilla saponin D in rat by ultra performance liquid
chromatography-quadrupole time-of-flight mass spectrometry
(UPLC/Q-TOF-MS/MS),” Fitoterapia, vol. 96, pp. 152–158, 2014.
[11] X. Zhang, D. I. Vernikovskaya, X.-M.Wang et al., “Quantitative
determination of pravastatin and itsmetabolite 3 alpha-hydroxy
pravastatin in plasma and urine of pregnant patients by LC-
MS/MS,” Biomedical Chromatography, vol. 30, no. 4, pp. 548–
554, 2016.
[12] A. L. Heffernan, K. Thompson, G. Eaglesham et al., “Rapid,
automated online SPE-LC-QTRAP-MS/MS method for the
simultaneous analysis of 14 phthalate metabolites and 5 bisphe-
nol analogues in human urine,” Talanta, vol. 151, pp. 224–233,
2016.
[13] N. P. Vidal, M. J. Manzanos, E. Goicoechea, and M. D. Guille´n,
“Farmed and wild sea bass (Dicentrarchus labrax) volatile
metabolites: a comparative study by SPME-GC/MS,” Journal of
the Science of Food and Agriculture, vol. 96, no. 4, pp. 1181–1193,
2016.
[14] M. Grapp, C. Sauer, C. Vidal, andD.Mu¨ller, “GC-MS analysis of
the designer drug 𝛼-pyrrolidinovalerophenone and its metabo-
lites in urine and blood in an acute poisoning case,” Forensic
Science International, vol. 259, pp. e14–e19, 2016.
[15] B. Zhang, M.-Z. Xie, L. Bruschweiler-Li, K. Bingol, and R.
Bru¨schweiler, “Use of charged nanoparticles in NMR-Based
metabolomics for spectral simplification and improved metab-
olite identification,” Analytical Chemistry, vol. 87, no. 14, pp.
7211–7217, 2015.
[16] Z.-X. Miao, M.-X. Jin, X. Liu et al., “The application of HPLC
and microprobe NMR spectroscopy in the identification of
metabolites in complex biological matrices,” Analytical and
Bioanalytical Chemistry, vol. 407, no. 12, pp. 3405–3416, 2015.
[17] H. Chu, A.-H. Zhang, Y. Han et al., “Metabolomics approach to
explore the effects of Kai-Xin-San on Alzheimer’s disease using
UPLC/ESI-Q-TOF mass spectrometry,” Journal of Chromatog-
raphy B, vol. 1015-1016, pp. 50–61, 2016.
[18] S. Indelicato, D. Bongiorno, L. Ceraulo et al., “Electrospray
ion mobility mass spectrometry of positively and negatively
charged (1R,2S)-dodecyl(2-hydroxy-1-methyl-2-phenylethyl)di-
methylammonium bromide aggregates,” Rapid Communica-
tions in Mass Spectrometry, vol. 30, no. 1, pp. 230–238, 2016.
[19] Z. Ma, X. Shi, G. Zhang, F. Guo, L. Shan, and J. Cai, “Metab-
olism and metabolic inhibition of xanthotoxol in human liver
microsomes,” Evidence-Based Complementary and Alternative
Medicine, vol. 2016, Article ID 5416509, 8 pages, 2016.
[20] Y.-Y. Zhang, Y. Liu, J.-W. Zhang et al., “Characterization of
human cytochrome P450 isoforms involved in the metabolism
of 7-epi-paclitaxel,” Xenobiotica, vol. 39, no. 4, pp. 283–292,
2009.
[21] N. Koga, C. Ohta, Y. Kato et al., “In vitrometabolism of nobile-
tin, a polymethoxy-flavonoid, by human liver microsomes and
cytochrome P450,”Xenobiotica, vol. 41, no. 11, pp. 927–933, 2011.
[22] Y. Moon, S.-Y. Kim, H.-Y. Ji et al., “Characterization of
cytochrome P450s mediating ipriflavone metabolism in human
liver microsomes,” Xenobiotica, vol. 37, no. 3, pp. 246–259, 2007.
[23] K. Krohn, I. Ahmed, M. John, M. C. Letzel, and D. Kuck, “Ster-
eoselective synthesis of benzylated prodelphinidins and their
diastereomers with use of the mitsunobu reaction in the prep-
aration of their gallocatechin precursors,” European Journal of
Organic Chemistry, no. 13, pp. 2544–2554, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
